The AJMC® Gastroenterology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the stomach, digestive tract, colon, and more.
Clarifying the Role of EEN Diet as Ulcerative Colitis Therapy
March 12th 2025There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, despite its good tolerability and low discontinuation rates, according to a systematic review.
Read More
Addressing Disparities in IBD Care to Reduce Costs and Improve Access
March 11th 2025Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments, increasing biosimilar adoption, and implementing policies that reduce financial disparities and improve long-term patient outcomes.
Read More
Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease
March 10th 2025Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.
Read More
Understanding the Bidirectional Relationship Between Anxiety and GI, Liver Conditions
March 5th 2025Health care providers must recognize and address the high prevalence of anxiety in gastroenterology (GI) and hepatology outpatients, as its bidirectional relationship with chronic conditions can significantly impact both physical and emotional wellbeing, according to a global review.
Read More
Crohn Disease Subtype, Ocular Manifestation Among Risk Factors for EIMs in IBD
February 24th 2025Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the highest risks among those with Crohn disease, ocular manifestations, or right-sided colonic involvement.
Read More
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Originator in IBD
February 20th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Read More
Abstracts Highlight Access Barriers, CV Risks Associated With IBD Care
February 11th 2025Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The Crohn’s & Colitis Congress 2025 explored these access issues as well as the potential cardiovascular complications related to IBD therapies.
Read More
PROSPERO Identifies Key Risk Factors for Gallstones in Crohn Disease
February 4th 2025The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition significantly increase the risk of gallstone disease in patients with Crohn disease.
Read More
New AGA Guidelines Recommend Risk-Based Prophylaxis for Hepatitis B Reactivation Monitoring
February 1st 2025The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for high- and moderate-risk patients.
Read More
Gene Variant, Season of Birth Identified as Celiac Disease Risk Factors
January 23rd 2025Children born in spring or summer with a specific gene variant may have a higher risk of celiac disease and lower levels of a key protein, according to a study, potentially helping future research on autoimmune diseases.
Read More
Study Finds Link Between COVID-19 and Elevated Risk of GI Disorders
January 14th 2025A study found that patients with COVID-19 may have a higher risk of developing new gastrointestinal (GI) disorders compared with matched controls, highlighting the need for further research on long-term GI effects post COVID-19 infection.
Read More
What Adjunct Therapies Are Most Effective for IBS, IBD?
January 13th 2025A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral therapy, may help alleviate persistent digestive symptoms and improve quality of life for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), alongside standard drug treatments.
Read More
Stable Patient Satisfaction Found After Switching From Humira or Biosimilar Adalimumab to CT-P17
January 7th 2025A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.
Read More